https://www.selleckchem.com/pr....oducts/Temsirolimus.
Screening tailored to PRS vs. biennial 50-74 screening had smaller positive effects on LYG (20%) and breast cancer deaths averted (11%) but also smaller increases in overdiagnoses (10%) and false positives (26%). Combined use of FH and PRS vs. B50-74 had the greatest increase in LYG (29%) and breast cancer deaths averted (18%). Our results suggest that breast cancer family history and polygenic risk could guide screening decisions before age 50 years among women at increased risk for breast cancer, but should consider expected incr
Curtir
Comentario
Compartilhar
